MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests
While MSD has proven remigromig non-inferior to Lucentis in terms of efficacy in DME, questions around its tolerability remain.
The post MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests appeared first on Clinical Trials Arena .